Celgene Defends Dismissal Of Cancer Drug Antitrust Suit

By Danielle Ferguson · October 28, 2026, 3:31 PM EDT

Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. urged the Second Circuit to uphold the dismissal of health plans' proposed antitrust class action alleging that the drugmaker fraudulently obtained patents for...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Louisiana Health Service & Indemnity Company et al v. Celgene Corporation et al

Case Number

1:23-cv-07871

Court

New York Southern

Nature of Suit

Anti-Trust

Date Filed

September 05, 2023

Case Title

The Cigna Group v. Celgene Corporation et al

Case Number

1:25-cv-05237

Court

New York Southern

Nature of Suit

Anti-Trust

Date Filed

June 24, 2025

Case Title

Louisiana Health Service & Indemnity Company v. Celgene Corporation

Case Number

26-1194

Court

Appellate - 2nd Circuit

Nature of Suit

Date Filed

May 01, 2026

Case Title

The Cigna Group v. Celgene Corporation

Case Number

26-1275

Court

Appellate - 2nd Circuit

Nature of Suit

 

Date Filed

May 07, 2026